(Q39328333)

English

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Enhanced immune responses and protection by vaccination with respiratory syncytial virus fusion protein formulated with CpG oligodeoxynucleotide and innate defense regulator peptide in polyphosphazene microparticles (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

S Garlapati

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

R Brownlie

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L Latimer

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

E Simko

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

R E W Hancock

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

L A Babiuk

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

V Gerdts

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

A Potter

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

S van Drunen Littel-van den Hurk

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

language of work or name

0 references

publication date

17 June 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

30

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

35

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

5206-5214

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22713718%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Pathogenesis of respiratory syncytial virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Respiratory syncytial virus infection in elderly and high-risk adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Viral and host factors in human respiratory syncytial virus pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

The path to a successful vaccine adjuvant--'the long and winding road'.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

CpG motifs in bacterial DNA and their immune effects

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

The novel adjuvant combination of CpG ODN, indolicidin and polyphosphazene induces potent antibody- and cell-mediated immune responses in mice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

CpG oligonucleotide, host defense peptide and polyphosphazene act synergistically, inducing long-lasting, balanced immune responses in cattle.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Formulation of bovine respiratory syncytial virus fusion protein with CpG oligodeoxynucleotide, cationic host defence peptide and polyphosphazene enhances humoral and cellular responses and induces a protective type 1 immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

A novel vaccine adjuvant comprised of a synthetic innate defence regulator peptide and CpG oligonucleotide links innate and adaptive immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Formulation with CpG oligodeoxynucleotides prevents induction of pulmonary immunopathology following priming with formalin-inactivated or commercial killed bovine respiratory syncytial virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Innovative strategies for co-delivering antigens and CpG oligonucleotides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Synthetic cationic peptide IDR-1002 provides protection against bacterial infections through chemokine induction and enhanced leukocyte recruitment

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Intranasal immunization of mice with a formalin-inactivated bovine respiratory syncytial virus vaccine co-formulated with CpG oligodeoxynucleotides and polyphosphazenes results in enhanced protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Expression of RNA virus proteins by RNA polymerase II dependent expression plasmids is hindered at multiple steps.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Biological challenges and technological opportunities for respiratory syncytial virus vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Immunogenicity and efficacy of recombinant RSV-F vaccine in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Efficacy and safety studies of a recombinant chimeric respiratory syncytial virus FG glycoprotein vaccine in cotton rats

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

CpG containing oligodeoxynucleotides are potent adjuvants for parenteral vaccination with the fusion (F) protein of respiratory syncytial virus (RSV).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Chitosan-based delivery systems for protein therapeutics and antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Combination adjuvants: the next generation of adjuvants?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Measurement of the Bc+ meson lifetime using the decay mode Bc+ --> J/Psie+nue

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Antibody responses in adult and neonatal BALB/c mice to immunization with novel Bordetella pertussis vaccine formulations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

A novel triple adjuvant formulation promotes strong, Th1-biased immune responses and significant antigen retention at the site of injection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.06.011

7 January 2021

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39328333&oldid=1817204799"